UNSPSC 51391740: Tazolol

This classification denotes a beta-adrenergic agonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 17B9PXO2SW. European Medicines Agency schedules Tobuterol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11135MIG. Tobuterol generally arises in the molecular formula C28H31NO5.

UNSPSC 51391740 Tazolol is a Commodity code that in recent state and local procurement activity covers pharmaceutical and drug management products, specifically naloxone and drug deactivation systems procured for public health and community safety initiatives. State and local health departments and county health agencies are the primary buyers under this code. The scope of work centers on the supply of pharmaceutical products and related systems designed to address opioid overdose response and controlled substance management, with vendors typically responsible for delivery logistics and ongoing supply chain management across quarterly or annual ordering cycles.

Seminole County, Florida posted a competitive IFB (IFB60459723LAS) in late June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building; the bid deadline was July 26, 2023, with bids evaluated on fixed-fee pricing and compliance with E-Verify and drug-free workplace requirements. The Texas Health and Human Services Commission issued an exploratory RFI (HHS0017013) in April 2026 focused on direct-to-manufacturer prescription fulfillment capabilities rather than product supply, signaling state-level interest in pharmacy benefit management innovation but showing limited direct relevance to the naloxone and drug deactivation commodity. Recent activity under this code is sparse and concentrated in Florida, with no additional jurisdictions or geographic clustering evident in the posted opportunities.